v3.25.2
STOCK-BASED COMPENSATION (Tables)
3 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation Expense

Total stock-based compensation expense recognized in the Company’s condensed consolidated statements of operations is classified as follows:

 

 

Three Months Ended March 31,

 

 

 

2025

 

 

2024

 

Cost of revenue

 

$

105,734

 

 

$

125,632

 

Research and development

 

 

93,425

 

 

 

139,050

 

Selling and marketing

 

 

196,488

 

 

 

80,925

 

General and administrative

 

 

101,517

 

 

 

268,508

 

Total stock-based compensation expense

 

$

497,164

 

 

$

614,115

 

Schedule of Restricted Stock Units The following table shows a summary of the Company's RSUs outstanding as of March 31, 2025 and December 31, 2024 as well as activity the year then ended:

 

 

RSUs

 

 

 

Number of Shares

 

 

Weighted Average Grant Date Fair Value

 

Unvested at December 31, 2024

 

 

4,562

 

 

$

223.07

 

RSUs vested (1)

 

 

(1,040

)

 

$

208.51

 

RSUs forfeited

 

 

(275

)

 

$

36.42

 

Unvested at March 31, 2025

 

 

3,247

 

 

$

243.54

 

(1)
Common stock underlying such vested RSUs was not yet formally issued by the Company.
Summary of Stock Options Activity A summary of stock option activity is as follows:

 

 

Number of Stock Options Outstanding

 

 

Weighted-Average Exercise Price

 

 

Weighted-Average Remaining Contractual Life (Years)

 

 

Aggregate Intrinsic Value

 

Options outstanding at December 31, 2024

 

 

218,430

 

 

$

40.80

 

 

 

7.1

 

 

$

7,375.15

 

Options cancelled or forfeited

 

 

(31,492

)

 

$

10.14

 

 

 

 

 

 

 

Options outstanding at March 31, 2025

 

 

186,938

 

 

$

45.96

 

 

 

4.0

 

 

$

 

Options exercisable at March 31, 2025

 

 

122,446

 

 

$

58.39

 

 

 

2.4

 

 

$

 

Options vested and expected to vest at March 31, 2025

 

 

186,938

 

 

$

45.96

 

 

 

4.0

 

 

$

 

Summary of Assumptions Utilized for Option Grants A summary of the weighted-average assumptions the Company utilized for option grants during the three months ended March 31, 2025 and 2024, respectively, are as follows:

 

 

Three Months Ended March 31,

 

 

 

2025

 

2024

 

Expected term (in years)

 

N/A

 

 

4.0

 

Expected volatility

 

N/A

 

47.8%

 

Risk-free interest rate

 

N/A

 

4.0%

 

Expected dividend yield

 

N/A

 

0.0%